← Eichor
Study identifier: NCT06275022 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Prospective Study on the Treatment of cLM Based on ICG Imaging

Condition: Lymphatic Malformation  ·  Sponsor: Nanjing Children's Hospital

PhaseNA
Planned participants110
Who can joinAll sexes, 30 Days to 16 Years
Healthy volunteersNo

About this study

The goal of this prospective randomized controlled study is to explore the role of indocyanine green-fluorescence imaging in management of cystic lymphatic malformation.. To clarify the application value of indocyanine green-fluorescence imaging in both diagnosis and treatment of cystic lymphatic malformation (cLM) in children, is helpful for exploring pathogenesis of cLM, and providing a clearer scientific basis for subsequent surgical intervention. It also provides alternative for the future diagnosis and treatment of cLM. Participants will receive indocyanine green-fluorescence imaging before operation, while the patients in control group will receive traditional operation. Researchers will compare difference in curative effect between two groups.

This description comes directly from the study's public registry record.

Talk to the study team

Tao Han, Dr.  ·  +86 186 5190 3495  ·  dr.hantao@njmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Children's hospital of Nanjing medical universityNanjing, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06275022